ORBITA Trials Are Not Justification to Promote a PCI-First Strategy in Nonacute Myocardial Ischemic Syndromes.

Autor:	Boden WE; Cardiology Section, Department of Medicine, VA Boston Healthcare System (W.E.B.)., De Caterina R; University of Pisa and Division of Cardiology, Pisa University Hospital, Italy (R.D.C.).
Jazyk:	angličtina
Zdroj:	Circulation. Cardiovascular quality and outcomes [Circ Cardiovasc Qual Outcomes] 2024 Sep; Vol. 17 (9), pp. e011268. Date of Electronic Publication: 2024 Sep 17.
DOI:	10.1161/CIRCOUTCOMES.124.011268
Abstrakt:	Competing Interests: Dr Boden receives research grant support from the Veterans Affairs Cooperative Studies Program and the National Heart, Lung, and Blood Institute. He has received research funding from AbbVie, Amarin Pharmaceuticals, Inc, Amgen, AstraZeneca, and Sanofi-Aventis. In addition, he has received speaking honoraria from Amarin, Amgen, Janssen Pharmaceuticals, Pfizer, and Servier. Dr De Caterina reports honoraria and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Novartis, Merck, Portola, Roche, AstraZeneca, Menarini, Guidotti, Milestone, Amarin, Noventure, Sanofi, and Amgen.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu